Can B Business Summary

Can B Corp, recently reorganized as Nascent Pharma Holdings, Inc. (NASC), operates as a diversified pharmaceutical intellectual property (IP) and wellness company. The firm generates revenue through a multi-pronged model: licensing its core cannabis patents for liquid formulations (targeting 10% royalties), direct-to-consumer and wholesale sales of hemp-derived CBD and nutritional superfoods under brands like Longevity and Canbiola, and a medical device rental program via its Duramed division. Its primary business segments are now bifurcated into IP monetization—focused on protecting and commercializing patents valued at over $122 million—and a legacy health and wellness portfolio that includes durable medical equipment and cannabinoid-based consumer products. In the competitive landscape, the company contends with established hemp and cannabis players such as Charlotte's Web, CV Sciences, and Tilray, as well as clinical-stage biotech firms like Esperion Therapeutics. NASC distinguishes itself by pivoting from a retail-centric CBD model toward a high-margin IP-holding strategy aimed at the broader pharmaceutical and beverage industries. Leadership is spearheaded by Chairman and CEO Marco Alfonsi, a financial services veteran with over two decades of experience in capital raising and business management. He is supported by Stanley L. Teeple, who serves as CFO and Director, bringing a specialized background in SEC compliance and corporate governance from his tenure at Solis Tek. The company’s strategic direction is heavily influenced by Principal IP Advisor and patent co-inventor Earnest Blackmon, the former CEO of United Cannabis Corporation, and Thomas A. Gallo, a senior advisor with 30 years of experience in financial engineering. The board and advisory teams feature notable figures such as NFL veteran Leonard Marshall on the Sports Advisory Board and Frederick Alger Boyer, Jr., an independent director who concurrently serves as CEO of Advance Care Medical. This leadership team is currently focused on leveraging its reorganization to secure litigation funding and partnerships to enforce its patent portfolio against major industry incumbents.